Clicky

Immunic, Inc.(IMUX)

Description: Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.


Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Autoimmune Disease Clinical Development Psoriasis Multiple Sclerosis Ulcer Ulcerative Colitis Metabolism Crohn's Disease Colitis Abdominal Pain Molecule Product Mayo Clinic Inflammatory And Autoimmune Diseases Primary Sclerosing Cholangitis Chronic Inflammatory And Autoimmune Diseases Relapsing Remitting Multiple Sclerosis

Home Page: www.immunic-therapeutics.com

IMUX Technical Analysis

1200 Avenue of the Americas
New York, NY 10036
United States
Phone: 332 255 9818


Officers

Name Title
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A Exec. Chairman
Dr. Daniel Vitt CEO, Pres & Director
Mr. Glenn Whaley CPA Chief Financial Officer
Dr. Andreas Muehler M.D., Ph.D. Chief Medical Officer
Dr. Hella Kohlhof Chief Scientific Officer
Jessica Breu Head of Investor Relations & Communications
Mr. Inderpal Singh Gen. Counsel
Mr. Patrick Walsh Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4258
Price-to-Sales TTM: 0
IPO Date: 2014-04-17
Fiscal Year End: December
Full Time Employees: 65
Back to stocks